Infusion of human placental derived mesenchymal stem cells in patients with Critical limb ischemia

Assessment effect of adaptive human placental mesenchymal stem cells transplantation on the improvement of Critical limb ischemia patients (clinical trial phase 1)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210221050446N1

Enrollment

Registered

2021-05-09

Start date

2022-04-19

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical limb ischemia. Other disorder of circulatory system

Interventions

Intervention group: Twice intramuscular injection of allogeneic mesenchymal stem cells into ischemia of patients with severe ischemia..

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Ankle brachial pressure index > 0.3. Rutherford class 4-6 Written informed consent

Exclusion criteria

Exclusion criteria: Diabetes mellitus with HbA1c > 7%. Major tissue loss in either leg. History of malignancy within five years ago

Design outcomes

Primary

Measure	Time frame
Safety. Timepoint: 1, 7, 30, 90, 180 days after injection. Method of measurement: Physical examinations and laboratory tests.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZeinab Shirbaghaee/saeed heidari keshel

Shahid Beheshti University of Medical Sciences

z.shirbaghaee@sbmu.ac.ir+98 21 2243 9770

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 9, 2026